Brain, Vol. 114, No. 2, 1057-1067, 1991
© 1991 Oxford University Press
research-article |
THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDY
4. APPLICATIONS TO PLANNING AND INTERPRETATION OF CLINICAL THERAPEUTIC TRIALS
Department of Clinical Neurological Sciences University of Western Ontario London, Ontario, Canada
Correspondence to:
Correspondence to: Dr G.C. Ebers, Clinical Neurological sciences, University Hospital 339 Windermere Road, London, Ontario N6A 5A5, Canada.
We used hypothetical entry criteria typical of those used in clinical therapeutic trials to determine the patients who would have been eligible among those followed in a clinic-based study of multiple sclerosis (MS) in London, Ontario, between 1972 and 1984. For these patients, we determined the observed frequency of deterioration by 1 point on the disability status scale (DSS) of Kurtzke, which is the most feasible and frequently used endpoint in clinical trials. We calculated the number of patients required for a randomized clinical trial to detect a significant result (alpha = 0.05) with 80% or 90% power based on the observed rate of deterioration. To assess the linearity of the DSS, we determined the frequency of progression and staying time at each level of the DSS. Overall the frequency of progression was lower and the staying times were longer at higher levels of disability. There was considerable intrapatient as well as interpatient variation in saying time. These data have major implications for the design and conduct of clinical therapeutic trials in MS.
Received December 19, 1989. Revised June 13, 1990. Accepted June 26, 1990.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Leone, S. Bonissoni, L. Collimedaglia, F. Tesser, S. Calzoni, A. Stecco, P. Naldi, and F. Monaco Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study Multiple Sclerosis, May 1, 2008; 14(4): 485 - 493. [Abstract] [PDF]
|
|
|
|
 |
|
 O. Gonen, T.A. Oberndorfer, M. Inglese, J.S. Babb, J. Herbert, and R.I. Grossman Reproducibility of Three Whole-Brain N-Acetylaspartate Decline Cohorts in Relapsing-Remitting Multiple Sclerosis AJNR Am. J. Neuroradiol., February 1, 2007; 28(2): 267 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J J Kragt, J M Nielsen, F A. van der Linden, B M. Uitdehaag, and C H Polman How similar are commonly combined criteria for EDSS progression in multiple sclerosis? Multiple Sclerosis, November 1, 2006; 12(6): 782 - 786. [Abstract] [PDF]
|
|
|
|
|
|
J Porcel, J Rio, A Sanchez-Betancourt, M J Arevalo, M Tintore, N Tellez, C Borras, C Nos, and X Montalban Long-term emotional state of multiple sclerosis patients treated with interferon beta Multiple Sclerosis, November 1, 2006; 12(6): 802 - 807. [Abstract] [PDF]
|
|
|
|
|
|
S Martinez-Yelamos, A Martinez-Yelamos, G M. Ozaeta, V Casado, O Carmona, and T. Arbizu Regression to the mean in multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 826 - 829. [Abstract] [PDF]
|
|
|
|
|
|
M. Trojano, P. Russo, A. Fuiani, D. Paolicelli, E. Di Monte, E. Granieri, G. Rosati, G. Savettieri, G. Comi, P. Livrea, et al. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFN{beta} exposure in multiple sclerosis Multiple Sclerosis, September 1, 2006; 12(5): 578 - 585. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Kremenchutzky, G. P. A. Rice, J. Baskerville, D. M. Wingerchuk, and G. C. Ebers The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease Brain, March 1, 2006; 129(3): 584 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C Ebers Natural history of primary progressive multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S8 - S15. [Abstract] [PDF]
|
|
|
|
 |
|
 R. K. Burt, B. A. Cohen, E. Russell, K. Spero, A. Joshi, Y. Oyama, W. J. Karpus, K. Luo, B. Jovanovic, A. Traynor, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores Blood, October 1, 2003; 102(7): 2373 - 2378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E L J Hoogervorst, M J Eikelenboom, B M J Uitdehaag, and C H Polman One year changes in disability in multiple sclerosis: neurological examination compared with patient self report J. Neurol. Neurosurg. Psychiatry, April 1, 2003; 74(4): 439 - 442. [Full Text] [PDF]
|
|
|
|
|
|
R A Rudick, G Cutter, and S Reingold The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials Multiple Sclerosis, October 1, 2002; 8(5): 359 - 365. [Abstract] [PDF]
|
|
|
|
 |
|
 P. O'Connor Key issues in the diagnosis and treatment of multiple sclerosis: An overview Neurology, September 24, 2002; 59(90063): S1 - 33. [Full Text]
|
|
|
|
|
|
A Ghezzi, C Pozzilli, M Liguori, M G Marrosu, N Milani, C Milanese, I Simone, and M Zaffaroni Prospective study of multiple sclerosis with early onset Multiple Sclerosis, April 1, 2002; 8(2): 115 - 118. [Abstract] [PDF]
|
|
|
|
|
|
C Liu and L D Blumhardt Randomized, double-blind, placebo-controlled study of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: a categorical disability trend analysis Multiple Sclerosis, February 1, 2002; 8(1): 10 - 14. [Abstract] [PDF]
|
|
|
|
|
|
G C Ebers NATURAL HISTORY OF MULTIPLE SCLEROSIS J. Neurol. Neurosurg. Psychiatry, December 1, 2001; 71(suppl_2): ii16 - ii19. [Full Text] [PDF]
|
|
|
|
|
|
S. H. Alusi, T. Z. Aziz, S. Glickman, M. Jahanshahi, J. F. Stein, and P. G. Bain Stereotactic lesional surgery for the treatment of tremor in multiple sclerosis: A prospective case-controlled study Brain, August 1, 2001; 124(8): 1576 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker Multiple Sclerosis N. Engl. J. Med., September 28, 2000; 343(13): 938 - 952. [Full Text] [PDF]
|
|
|
|
|
|
D T Grima, G W Torrance, G Francis, G Rice, A J Rosner, and L Lafortune Cost and health related quality of life consequences of multiple sclerosis Multiple Sclerosis, April 1, 2000; 6(2): 91 - 98. [Abstract] [PDF]
|
|
|
|
|
|
C. Liu and L. D Blumhardt Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts J. Neurol. Neurosurg. Psychiatry, April 1, 2000; 68(4): 450 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cohen, J. S. Fischer, D. M. Bolibrush, A. J. Jak, J. E. Kniker, L. A. Mertz, T. T. Skaramagas, and G. R. Cutter Intrarater and interrater reliability of the MS functional composite outcome measure Neurology, February 22, 2000; 54(4): 802 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Parkin, A. Jacoby, P. McNamee, P. Miller, S. Thomas, and D. Bates Treatment of multiple sclerosis with interferon beta : an appraisal of cost-effectiveness and quality of life J. Neurol. Neurosurg. Psychiatry, February 1, 2000; 68(2): 144 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C H POLMAN, D H MILLER, W I MCDONALD, and A J THOMPSON Treatment recommendations for interferon-beta in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 1999; 67(5): 561 - 564. [Full Text]
|
|
|
|
|
|
C. Liu and L. D Blumhardt Randomised, double blind, placebo controlled study of interferon beta -1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves J. Neurol. Neurosurg. Psychiatry, October 1, 1999; 67(4): 451 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M J Hohol, E J Orav, and H L Weiner Disease steps in multiple sclerosis: a longitudinal study comparing Disease Steps and EDSS to evaluate disease progression Multiple Sclerosis, October 1, 1999; 5(5): 349 - 354. [Abstract] [PDF]
|
|
|
|
|
|
W I McDonald Physicians, subsequence and consequence J. Neurol. Neurosurg. Psychiatry, September 1, 1999; 67(3): 282 - 289. [Full Text]
|
|
|
|
|
|
D. S Goodin and Northern California MS Study Group Survey of multiple sclerosis in Northern California Multiple Sclerosis, April 1, 1999; 5(2): 78 - 88. [Abstract] [PDF]
|
|
|
|
|
|
N. A SIMONIAN, A. MCALLISTER, J. LULL;, C. LIU, L. D BLUMHARDT, and A. L. W. PO "Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis J. Neurol. Neurosurg. Psychiatry, April 1, 1999; 66(4): 553 - 554. [Full Text]
|
|
|
|
|
|
P. Rudge The value of natural history studies of multiple sclerosis Brain, April 1, 1999; 122(4): 591 - 592. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Cottrell, M. Kremenchutzky, G. P. A. Rice, W. J. Koopman, W. Hader, J. Baskerville, and G. C. Ebers The natural history of multiple sclerosis:a geographically based study: 5. The clinical features and natural history of primary progressive multiple sclerosis Brain, April 1, 1999; 122(4): 625 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Cottrell, M. Kremenchutzky, G. P. A. Rice, W. Hader, J. Baskerville, and G. C. Ebers The natural history of multiple sclerosis: a geographically based study: 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis Brain, April 1, 1999; 122(4): 641 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Myhr, T. Riise, F. E. G. Lilleas, T. G. Beiske, E. G. Celius, A. Edland, D. Jensen, J. P. Larsen, R. Nilsen, M. W. Nortvedt, et al. Interferon-{alpha}2a reduces MRI disease activity in relapsing-remitting multiple sclerosis Neurology, March 1, 1999; 52(5): 1049 - 1049. [Abstract] [Full Text]
|
|